Skip to main content

Table 1 Characteristics of included studies. Abbreviations: NSCLC (non-small lung cancer); S-NSCLC (squamous non-small lung cancer); NS-NSCLC (non-squamous non-small lung cancer); RCC (renal cell cancer); H&N (head & neck); NR (not reported); Q (every); W (weeks)

From: Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis

  Study Name Drug Phase Malignancy First line Arm 1 Arm 2 Arm 3 Patient’ number Age median Age range Age mean n (%) < 65 y n (%) ≥ 65 y
Rittmeyer 2016 [33] OAK Atezolizumab 3 NSCLC N Atezolizumab 1200 mg Q 3 W Docetaxel
75 mg/m2 Q 3 W
  850 64 33–85 63 453 (53) 397 (47)
Fehrenbacher 2016 [26, 34] POPLAR Atezolizumab 2 NSCLC N Atezolizumab 1200 mg Q 3 W Docetaxel
75 mg/m2 Q 3 W
  287 62 36–84 61.5 174 (61) 113 (39)
Brahmer 2015 [5] Checkmate-017 Nivolumab 3 S-NSCLC N Nivolumab 3 mg/kg Q 2 W Docetaxel
75 mg/m2 Q 3 W
  272 63 39–85 63 152 (56) 120 (44)
Borghaei 2015 [6] Checkmate-057 Nivolumab 3 NS-NSCLC N Nivolumab 3 mg/kg Q 2 W Docetaxel
75 mg/m2 Q 3 W
  582 62 21–85 NR 339 (58) 243 (42)
Motzer 2015 [4] Checkmate-025 Nivolumab 3 RCC N Nivolumab 3 mg/kg Q 2 W Everolimus 10 mg daily   821 62 18–88 61.3 497 (61) 324 (39)
Robert 01–2015 [29] Checkmate-066 Nivolumab 3 Melanoma Y Nivolumab
3 mg/kg Q 2 W
Dacarbazine
1000 mg/m2 Q 3 W
  418 65 18–87 62.7 200 (48) 218 (52)
Ferris 2016 [2] Checkmate-141 Nivolumab 3 H&N N Nivolumab
3 mg/kg Q 2 W
Chemotherapy   361 60 28–83 59.1 248 (69) 113 (31)
Herbst 2016 [8] Keynote-010 Pembrolizumab 2/3 NSCLC N Pembrolizmab
2 mg/kg Q 3 W
Pembrolizumab 10 mg/kg Q 3 W Docetaxel
75 mg/m2 Q 3 W
1033 NR NR 62 604 (58) 429 (42)
Robert 06–2015 [9] Keynote-006 Pembrolizumab 3 Melanoma N Pembrolizumab
10 mg/kg Q 2 W
Pembrolizumab
10 mg/kg Q 3 W
Ipilimumab
3 mg/kg Q 3 W
834 NR NR 60.3 467 (56) 367 (44)